$2.16
(Market cap
$6,125 Mln
Revenue (TTM)
$1,546 Mln
P/E Ratio
22.5
P/B Ratio
5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
44.03
-
EV/EBITDA
13.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$4.1
-
Face value
--
-
Shares outstanding
65,106,082
10 Years Aggregate
CFO
$936.70 Mln
EBITDA
$716.70 Mln
Net Profit
$474.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lantheus Holdings (LNTH)
| 44.6 | 19.4 | 43.0 | 17.7 | -1.1 | 36.0 | 46.0 |
|
BSE Sensex*
| -11.9 | -3.8 | -10.8 | -9.5 | 6.3 | 8.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Lantheus Holdings (LNTH)
| -25.6 | 43.9 | 21.7 | 76.4 | 114.2 | -34.2 | 31.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lantheus Holdings (LNTH)
|
96.2 | 6,124.5 | 1,546.2 | 279.0 | 15.0 | 23.9 | 22.5 | 5.0 |
| 8.2 | 5,441.6 | 6,552.2 | -551.4 | -4.3 | -9.9 | -- | 1.0 | |
| 255.5 | 6,838.7 | 2,589.9 | 168.8 | 21.4 | 2.5 | 42.5 | 1.0 | |
| 44.7 | 6,586.8 | 3,458.5 | -10.3 | 1.9 | -0.5 | -- | 2.7 | |
| 24.3 | 3,938.0 | 2,808.1 | 67.7 | 6.8 | 2.2 | 59 | 1.3 | |
| 136.4 | 7,950.8 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 11.7 | |
| 118.3 | 3,839.6 | 787.9 | -27.8 | -2.7 | -19.6 | -- | 24.6 | |
| 178.6 | 9,347.9 | 1,558.5 | 76.3 | 19.1 | 9.5 | 44.1 | 11.8 | |
| 322.8 | 12,653.3 | 1,454.3 | 171.1 | 11.1 | 12.1 | 74.1 | 8.6 | |
| 113.6 | 6,538.2 | 763.3 | 51.4 | 11.6 | 2.5 | 127.4 | 3.3 |
Shareholding Pattern
View DetailsAbout Lantheus Holdings (LNTH)
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable... ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. Address: 201 Burlington Road, Bedford, MA, United States, 01730 Read more
-
CEO & Director
Mr. Brian A. Markison
-
CEO & Director
Mr. Brian A. Markison
-
Headquarters
Bedford, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Lantheus Holdings (LNTH)
What is the current share price of Lantheus Holdings Inc (LNTH) Today?
The share price of Lantheus Holdings Inc (LNTH) is $96.23 (NASDAQ) as of 12-May-2026 16:06 EDT. Lantheus Holdings Inc (LNTH) has given a return of -1.07% in the last 3 years.
What is the current PB & PE ratio of Lantheus Holdings Inc (LNTH)?
The P/E ratio of Lantheus Holdings Inc (LNTH) is 22.45 times as on 12-May-2026, a 49 discount to its peers’ median range of 44.03 times.
The P/B ratio of Lantheus Holdings Inc (LNTH) is 5.00 times as on 12-May-2026, a 72 premium to its peers’ median range of 2.91 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.90
|
4.05
|
|
2024
|
19.82
|
5.69
|
|
2023
|
13.30
|
5.33
|
|
2022
|
124.37
|
7.81
|
|
2021
|
-27.44
|
4.21
|
What is the 52 Week High and Low of Lantheus Holdings Inc (LNTH)?
The 52-week high and low of Lantheus Holdings Inc (LNTH) are Rs 96.28 and Rs 47.25 as of 13-May-2026.
What is the market cap of Lantheus Holdings Inc (LNTH)?
Lantheus Holdings Inc (LNTH) has a market capitalisation of $ 6,125 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Lantheus Holdings Inc (LNTH)?
Before investing in Lantheus Holdings Inc (LNTH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.